ABCA1 and stroke disorder: The administration of HDL3 or ApoE2 into the ischemic brain of ABCA1-B/-B stroke mice starting 24 h and daily for 14 days significantly improve neurological functional outcome at 14 and 21 days after stroke (Figure 2B, p < 0.05, n = 9/group).